Cagrilintide — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 5 sources[1,2,3,4,5].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre… | The Lancet | 2021 |
| 2 | Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in… | The Lancet | 2023 |
| 3 | Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with… | Diabetes Care | 2003 |
| 4 | Protein aggregation — pathways and influencing factors | International Journal of Pharmaceutics | 2010 |
| 5 | Rational design of stable lyophilized protein formulations: some practical advice | Pharmaceutical Research | 1997 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 7 | CAGRI-PH2-DOSEFIND · AMY-PH1-ORAL · AMY-PH1B-SC · CAGRI-PH2-DOSEFIND-PK · CAGRI-PH2-DOSEFIND-RENAL-IMP · CAGRI-PH2-DOSEFIND-HEPATIC-IMP · CAGRI-PH2-DOSEFIND-DDI |
| Evidence syntheses | 1 | Amylin analogues as monotherapy and in combination |
| Comment periods | 1 | Draft monograph: Cagrilintide |
| Indication assessments | 2 | Obesity · Type 2 diabetes |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino DM, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet 2021;398(10317):2160–2172. doi:10.1016/S0140-6736(21)01751-7 · PMID 34798060
- Frías JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet 2023;402(10403):720–730. doi:10.1016/S0140-6736(23)01163-7 · PMID 37364591
- Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26(3):784–790. doi:10.2337/diacare.26.3.784 · PMID 12610038
- Wang W, Nema S, Teagarden D. Protein aggregation — pathways and influencing factors. International Journal of Pharmaceutics 2010;390(2):89–99. doi:10.1016/j.ijpharm.2010.02.025 · PMID 20188795
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceutical Research 1997;14(8):969–975. doi:10.1023/a:1012180707283 · PMID 9279875
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.